Vanguard Global Advisers’s Ovid Therapeutics OVID Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$355K Buy
142,707
+72,180
+102% +$189K ﹤0.01% 2251
2026
Q2
$190K Buy
70,527
+46,788
+197% +$121K ﹤0.01% 2516
2026
Q1
$52.7K Buy
+23,739
New +$42.4K ﹤0.01% 2997

Other funds holding OVID

Vanguard Global Advisers's OVID Position: Q3 2026 in Review

Vanguard Global Advisers increased its Ovid Therapeutics (OVID) stake by 102% in Q3 2026, buying an estimated $189K and bringing the position to 142,707 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #2251.

Vanguard Global Advisers first reported a position in OVID in Q1 2026 and has held it in 3 quarters since. 127 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • Vanguard Global Advisers held 142,707 shares of Ovid Therapeutics worth $355K as of Q3 2026.
  • Vanguard Global Advisers bought 72,180 Ovid Therapeutics shares in Q3 2026, an estimated $189K.
  • Ovid Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2251 holding.
  • Vanguard Global Advisers first reported a position in Ovid Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 127 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.